Market openADR
Adagene/$ADAG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adagene
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Ticker
$ADAG
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
138
ISIN
US0053291078
Website
Adagene Metrics
BasicAdvanced
$83M
-
-$0.74
0.50
-
Price and volume
Market cap
$83M
Beta
0.5
52-week high
$3.20
52-week low
$1.33
Average daily volume
16K
Financial strength
Current ratio
2.299
Quick ratio
2.231
Long term debt to equity
1.108
Total debt to equity
36.604
Interest coverage (TTM)
-42.20%
Management effectiveness
Return on assets (TTM)
-21.92%
Return on equity (TTM)
-55.21%
Valuation
Price to revenue (TTM)
772.588
Price to book
1.65
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-2.681
Growth
Revenue change (TTM)
-99.43%
Earnings per share change (TTM)
69.66%
3-year revenue growth (CAGR)
-78.35%
3-year earnings per share growth (CAGR)
-25.96%
What the Analysts think about Adagene
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adagene stock.
Adagene Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Adagene Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Adagene News
AllArticlesVideos
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
GlobeNewsWire·3 weeks ago
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·3 weeks ago
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adagene stock?
Adagene (ADAG) has a market cap of $83M as of May 16, 2025.
What is the P/E ratio for Adagene stock?
The price to earnings (P/E) ratio for Adagene (ADAG) stock is 0 as of May 16, 2025.
Does Adagene stock pay dividends?
No, Adagene (ADAG) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Adagene dividend payment date?
Adagene (ADAG) stock does not pay dividends to its shareholders.
What is the beta indicator for Adagene?
Adagene (ADAG) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.